September 9, 2026
Pharvaris said its drug deucrictibant met its main goal in a Phase 3 study for preventing attacks of hereditary angioedema.
What happened
Pharvaris announced statistically significant and clinically meaningful topline results from its CHAPTER-3 pivotal Phase 3 study. The trial evaluated an extended-release tablet of deucrictibant for preventing HAE attacks. Shares of Pharvaris ended the day down 0.5 percent, a move larger than only 15 percent of its trading days over the past three years.
Why it matters
Positive pivotal data puts Pharvaris a step closer to offering a new oral preventive option for HAE patients, who currently rely largely on injections. The small share move on the day suggests the market priced in a good result, muting a fresh rally.
The case against
The Phase 3 headline does not yet come with the full safety and efficacy detail that regulators and doctors need to judge the drug against existing options. Even a statistically meaningful result must show it can compete commercially in a crowded HAE market.
What settles it
Full data presentation at a medical meeting, where doctors can assess the magnitude of attack reduction and any safety signals.